<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04742361</url>
  </required_header>
  <id_info>
    <org_study_id>ABX-CT-303</org_study_id>
    <nct_id>NCT04742361</nct_id>
  </id_info>
  <brief_title>Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer</brief_title>
  <official_title>Phase III Study of [18F]PSMA-1007 Positron Emission Tomography for the Detection of Prostate Cancer Lesions in Patients With Biochemical Recurrence After Previous Definitive Treatment for Localized Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ABX advanced biochemical compounds GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ABX advanced biochemical compounds GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the diagnostic performance and safety of [18F]PSMA-1007 PET/CT imaging&#xD;
      in patients with suspected recurrence of prostate cancer after previous definitive treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 8, 2021</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Region-level positive predictive value (PPV) of [18F]PSMA-1007 using a combined standard of truth (SOT)</measure>
    <time_frame>Within 6 months after PET/CT</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-level correct detection rate of [18F]PSMA-1007</measure>
    <time_frame>Within 6 months after PET/CT</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostate Cancer Recurrent</condition>
  <arm_group>
    <arm_group_label>[18F]PSMA-1007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single intravenous administration of [18F]PSMA-1007 for Positron Emission Tomography (PET) scan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[18F]PSMA-1007</intervention_name>
    <description>diagnostic radiopharmaceutical for PET scan</description>
    <arm_group_label>[18F]PSMA-1007</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male with original diagnosis of adenocarcinoma of the prostate with prior definitive&#xD;
             therapy&#xD;
&#xD;
          -  Suspicion of recurrence or persistence&#xD;
&#xD;
               -  after radiotherapy or cryotherapy: 3 consecutive PSA rises and/or PSA rise by 2.0&#xD;
                  ng/mL or more above nadir (ASTRO-Phoenix)&#xD;
&#xD;
               -  after prostatectomy, PSA &gt; 0.2 ng/mL on 2 or more determinations (recurrence), or&#xD;
                  failure of PSA to fall to undetectable levels post-prostatectomy (persistence)&#xD;
                  (American Urological Association)&#xD;
&#xD;
          -  For patients who previously had radical prostatectomy, salvage radiotherapy is one&#xD;
             likely treatment plan; for patients who initially underwent radiotherapy (including&#xD;
             brachytherapy), confirmation of low volume disease is needed to define (local)&#xD;
             treatment.&#xD;
&#xD;
          -  Life expectancy of 6 months or more as judged by the investigator&#xD;
&#xD;
          -  Willing and able to undergo all study procedures&#xD;
&#xD;
          -  Informed consent in writing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age: less than18 years&#xD;
&#xD;
          -  Contraindications to any of the ingredients of [18F]PSMA-1007&#xD;
&#xD;
          -  Close affiliation with the investigational site&#xD;
&#xD;
          -  At the time of enrolment into this study, participating in another therapeutic&#xD;
             clinical trial or has completed study participation in another therapeutic clinical&#xD;
             trial within 5 days of enrolment into this trial&#xD;
&#xD;
          -  Having been previously enrolled in this clinical trial&#xD;
&#xD;
          -  Mental conditions rendering the subject incapable to understand the nature, scope, and&#xD;
             consequences of the trial&#xD;
&#xD;
          -  Being clinically unstable or requiring emergency treatment&#xD;
&#xD;
          -  Patients who are unwilling to consider a biopsy if clinically recommended&#xD;
&#xD;
          -  Patients who are unable to undergo a PET/CT scan&#xD;
&#xD;
          -  Patients for whom systemic therapy is the most likely course regardless of PET&#xD;
             findings.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexander Hoepping, Dr.</last_name>
    <phone>+49 3528 4041 60</phone>
    <email>hoepping@abx.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>RUMC</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inselspital, Universit√§tsspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

